Skip to main navigation
Menu
Main navigation
Advocacy
Issue Overview
#Rx4StateSavings
#4GRxANTED
#MarkupMadness
State Advocacy
GDUFA/BsUFA User Fees
Biosimilars Council
Action Center
Our Impact
Join
About Us
Generic Quality
About AAM
Our Team
Our Members
Generic Medicines
Biosimilars Council
Meet Our Board
Social Commitment
Careers
Contact Us
Stories
Events
Access! 2025
GRx+Biosims 2024
Resources
All Resources
Drug Shortages White Paper
2023 Savings Report
Biosimilars Patient Resource Center
Biosimilar Research & Studies
Press Releases
Blog
Founders Blogs
Amicus Briefs
Take Action
Search
Close
Breadcrumb
Association for Accessible Medicines
Resources
Resources
Share
Find up-to-date information on generics and biosimilars
Filter Resources
Issues
Biosimilar User Fee Act (BsUFA)
Biosimilars
Complex Generics
Drug Approval Process (GDUFA)
Drug Prices
Drug Shortages
Generic Drug Labeling
Generic Supply Chain
IP Issues
Low Income Subsidies (LIS in Part D)
Medicaid
Medicare
NAFTA
Patent Reform
Patient Stories
Pharmaceutical Waste Take Back
Preventing Drug Abuse
Quality
REMS/Sample Acquisition Remedies
State Initiatives
Tariffs
Trade
Transparency
User Fees
Resource Type
Blog
Amicus Brief
Press Release
Infographic
Video
Report
Fact Sheet
Presentation
Press Release
Apr 27, 2017
| Erica Klinger
Bill to Lower Drug Prices Gains Bipartisan Momentum in the House and Senate
Press Release
Apr 27, 2017
| Erica Klinger
Expediting Approval of Generic Applications and Stopping REMS Abuse Among Top Priorities for Nation’s Leading Patient Advocacy Group
Blog
Apr 17, 2017
| Erica Klinger
REMS Abuse Impeding Patient Access to Generic Drugs – Myths and Facts
Blog
Apr 16, 2017
| Model B
What They Are Saying - Blocking Access to Samples
Blog
Apr 11, 2017
| Erica Klinger
Learn to manage the GDUFA landscape at our CMC Workshop
Blog
Apr 10, 2017
| Erica Klinger
Veto Maryland House Bill 631, Which Would Harm Patients by Chilling Generic Drug Competition
Press Release
Apr 10, 2017
| Erica Klinger
Protect Generic Drug Savings for Maryland Patients and Taxpayers
Press Release
Apr 7, 2017
| Erica Klinger
AAM Supports Bipartisan Legislation to Contain Costs for Medicines by Curbing Abusive Behavior of Brand Drug Companies
Blog
Apr 6, 2017
| Erica Klinger
AAM Group Letter of Support for FAST Generics Act
Blog
Mar 28, 2017
| Erica Klinger
Recapping: The Future for Biosimilars
Press Release
Mar 14, 2017
| Erica Klinger
Seema Verma Approved as CMS Administrator - Let's Preserve and Strengthen Medicare and Medicaid Savings
Press Release
Mar 13, 2017
| Erica Klinger
AAM Applauds Nomination of Dr. Scott Gottlieb to Lead the Food and Drug Administration
Load More
Advocacy
Issue Overview
#Rx4StateSavings
#4GRxANTED
#MarkupMadness
State Advocacy
GDUFA/BsUFA User Fees
Biosimilars Council
Action Center
Our Impact
Join
About Us
Generic Quality
About AAM
Our Team
Our Members
Generic Medicines
Biosimilars Council
Meet Our Board
Social Commitment
Careers
Contact Us
Stories
Events
Access! 2025
GRx+Biosims 2024
Resources
All Resources
Drug Shortages White Paper
2023 Savings Report
Biosimilars Patient Resource Center
Biosimilar Research & Studies
Press Releases
Blog
Founders Blogs
Amicus Briefs
Take Action